Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
health economics
health policy
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
11 06 2020
11 06 2020
Historique:
entrez:
14
6
2020
pubmed:
14
6
2020
medline:
16
2
2021
Statut:
epublish
Résumé
Norway is one of several European countries that lacks a national value set and scoring algorithm for the EuroQol five dimensions (EQ-5D). Recent studies have found differences between countries in terms of health values or preferences for health states described by instruments such as the EQ-5D. The project aims to model a national value set for the five level version of the EQ-5D based on values elicited from a representative sample of the Norwegian adult general population in terms of region, age, sex and level of education. Using a sampling strategy supporting the collection of values for both hypothetical and experienced health states, the study will have the additional aim of assessing the feasibility of collecting experience-based values in accordance with the latest EQ-5D valuation study protocol, and comparing values with those given for hypothetical health states. Multistage random sampling and quota-sampling will contribute to representativeness. To increase the number of valuations of experienced health states, those with less than perfect health will be oversampled, increasing the total number of interviews from 1000 to 1300-1500. The most recent EQ-5D valuation protocol will be followed which includes computer assisted face-to-face, one-to-one interviews and use of composite time trade-off and discrete choice experiments. The study has been reviewed and found to be outside of the scope of the ethics committee and thus not in need of ethical approval. The study findings will be disseminated through peer-reviewed publications, conference presentations and summaries for key stakeholders and partners in the field. The scoring algorithms will be available for widely used statistical software.
Identifiants
pubmed: 32532768
pii: bmjopen-2019-034683
doi: 10.1136/bmjopen-2019-034683
pmc: PMC7295408
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e034683Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Value Health. 2019 Jan;22(1):23-30
pubmed: 30661630
Value Health. 2017 Sep;20(8):1150-1156
pubmed: 28964448
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Value Health. 2017 Mar;20(3):466-473
pubmed: 28292492
Value Health. 2017 Apr;20(4):662-669
pubmed: 28408009
Pharmacoeconomics. 2017 Nov;35(11):1153-1165
pubmed: 28695543
Patient. 2018 Jun;11(3):253-270
pubmed: 29305706
Pharmacoeconomics. 2018 Nov;36(11):1345-1353
pubmed: 30051267
Value Health Reg Issues. 2014 Sep;4:19-23
pubmed: 29702801
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Pharmacoeconomics. 2016 Oct;34(10):993-1004
pubmed: 27084198
Health Qual Life Outcomes. 2017 Jul 7;15(1):138
pubmed: 28683747
Value Health Reg Issues. 2017 May;12:20-23
pubmed: 28648311
Pharmacoeconomics. 2011 Jun;29(6):521-34
pubmed: 21247225
Eur Spine J. 2005 Dec;14(10):1000-7
pubmed: 15843969
Pharmacoeconomics. 2014 Apr;32(4):367-75
pubmed: 24477679
Qual Life Res. 2016 Feb;25(2):323-333
pubmed: 26242249
Health Qual Life Outcomes. 2015 Jul 02;13:94
pubmed: 26135391
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Eur J Health Econ. 2018 Dec;19(9):1207-1211
pubmed: 29671142
Qual Life Res. 2017 May;26(5):1197-1208
pubmed: 27796774
Qual Life Res. 2015 Mar;24(3):693-703
pubmed: 25246184
Patient. 2018 Apr;11(2):235-247
pubmed: 29019161
Appl Health Econ Health Policy. 2005;4(4):201-8
pubmed: 16466271
Med Decis Making. 2007 Jul-Aug;27(4):406-13
pubmed: 17585007
Med Care. 2014 Apr;52(4):307-13
pubmed: 24374420
Med Care. 2016 Jan;54(1):98-105
pubmed: 26492214
BMJ. 2002 Jun 15;324(7351):1417
pubmed: 12065262
Health Econ. 2000 Mar;9(2):109-26
pubmed: 10721013
J Intern Med. 2016 Feb;279(2):141-53
pubmed: 26306802
Health Policy. 2016 Mar;120(3):246-51
pubmed: 26851991
Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):551-558
pubmed: 29958008
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
Ann Epidemiol. 2007 Sep;17(9):643-53
pubmed: 17553702
Nature. 2009 Nov 5;462(7269):35
pubmed: 19890311
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Health Econ. 2011 Dec;20(12):1407-16
pubmed: 20967923
Qual Life Res. 2016 Jul;25(7):1845-52
pubmed: 26961008
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Value Health. 2014 Jun;17(4):445-53
pubmed: 24969006
Qual Life Res. 2010 Oct;19(8):1145-54
pubmed: 20496167
Qual Life Res. 2020 Jun;29(6):1465-1482
pubmed: 32016683
Health Econ. 2018 Jan;27(1):39-49
pubmed: 29063633
Pharmacoeconomics. 2019 May;37(5):715-725
pubmed: 30535779
Qual Life Res. 2014 Mar;23(2):431-42
pubmed: 23975375